SpringWorks Therapeutics (SWTX)
(Delayed Data from NSDQ)
$36.77 USD
-0.51 (-1.37%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $36.74 -0.03 (-0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
SpringWorks Therapeutics [SWTX]
Reports for Purchase
Showing records 81 - 100 ( 193 total )
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Another Contender in the RING in the Desmoid Division
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Niro Nears the Mark on MM, Longer Desmoid Data
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Top-Line DeFi Results; Nirogacestat Improves ORR and Keratopathy for BLENREP; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Nirogacestat Delivers on DeFi; DREAMMs of ASCO
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Potentially Transformative Second Quarter; 1Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R